PR Newswire·Oct 30, 2026, 10:20 AM ET

BioArctic's Nomination Committee appointed

BioArctic AB announced the composition of its Nomination Committee for the 2027 Annual General Meeting on October 30, 2026.
The committee consists of representatives from the three largest shareholders by voting rights as of September 30, 2026, plus the Chair of the Board.
Margareta Öhrvall (appointed by Demban AB) & Pär Gellerfors (appointed by Ackelsta AB) serve as members.
Thomas Ehlin (representing Fjärde AP-fonden) serves as the Chair of the Nomination Committee.
These shareholders collectively hold approximately 57% of shares & 82% of votes in the company.
Proposals for the committee must be received by January 15, 2027, via email or post.
BioArctic's Annual General Meeting 2027 is scheduled for May 27, 2027, at 4:30 pm CEST in Stockholm.
Requests to include matters in the AGM notice must be submitted by April 15, 2027.
BioArctic is a Swedish biopharma company focused on neurodegenerative diseases & holds the invention rights for Leqembi®.